Subsequent immunohistochemical analysis in a series of 153 unselected cases of breast cancer confirmed the more frequent expression of MAGE-A and NY-ESO-1 protein in ER-negative tumors, and similar findings were also observed by analyzing 19 cases of ER, PR and HER2 triple-negative breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.